Amgen (AMGN) Dumps AstraZeneca PLC (AZN) Pact After Patients Developed Suicidal Thoughts THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE:AZN). Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was based on events of suicidal ideation and behavior in the brodalumab program, which Amgen believes likely would necessitate restrictive labeling. Ahh yes the GENIUS of MedImmune - no new drugs just huge amounts of ego - Right John ??
Fortunately Amgen over-reacted, this is an absolutely viable development program. We have reanalyzed the data - at the mid dose there are no events.
ASStraZeneca knows that a few deaths cant stop a high priced mediocre drug - that's our specialty. Full steam Ahead !!
Meeeeee toooo! Just hanging, doing my thing casually, getting signatures, driving around, doing a little FMQ talking and waiting for the Holy Grail of severance.